Enhancing prediction of severe adverse effects early in the drug development pipeline
Around 9 of every 10 drug candidates fail to win approval. Drugs can often progress into phase III clinical trials - trials with patients - before some rare but potentially lethal side effects become apparent. This late-stage discovery has significant consequences for the time and cost of drug development. Safety pharmacology is a rapidly developing discipline that seeks to predict whether a drug is likely to be found unsafe if administered to human beings. INSPIRE plans to advance the field of safety pharmacology with a focus on cardiovascular events. Bringing together interrelated expertise including academics, pharmaceutical companies, hospitals, and regulators, the team is fostering innovation among early stage researchers to detect and minimise cardiovascular adverse events early in the pipeline.
Call for proposal
See other projects for this call
Funding SchemeMSCA-ITN-ETN - European Training Networks
78230 LE P Le Pecq
2333 BD Leiden